The Readout Loud

Latest Episodes:

335: A deep dive on Makary, Vertex's pain data, & 2025 predictions Dec 19, 2024

Show notes

STAT's FDA reporter Lizzy Lawrence joins us to discuss her profile of Marty Makary, Trump's nominee for FDA commissioner. Then, we discuss the results of Vertex's latest pain drug trial, the medication launches to watch in 2025, and present our burning questions for the biopharma industry.

334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children Dec 12, 2024

Show notes

Washington correspondent John Wilkerson joins to discuss why drugmakers have not lobbied against Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services, despite his repeated criticisms of the pharmaceutical industry. We also bring on our colleague Jason Mast to talk about the major hurdles in the field of gene therapy and how one father is trying to overcome them.

333: An H5N1 bird flu update and talent scarcity in the radiopharma field Dec 05, 2024

Show notes

You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than eight months ago. Well, bird flu is still here and the number of reported cases in people is growing. STAT’s infectious disease reporter Helen Branswell joins us for an update. But first, we break down the results from a GLP-1 showdown study that compared Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy. Allison shares her recent reporting on a talent shortage that is posing new challenges to the fast-growing radiopharmaceutical industry.

332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner? Nov 21, 2024

Show notes

Atlas Venture Partner Bruce Booth joins the podcast to discuss his annual year in review report, the influence of China, and what the new Trump administration might mean for innovation. Adam and Allison also recap the latest news in the life sciences, including a new science chief at Pfizer, a new job for Ned Sharpless, and the ongoing presidential appointments.

331: AbbVie’s stumble, Amgen’s tumble and more election fallout Nov 14, 2024

Show notes

Why are AbbVie executives feeling the M&A blues? What does it take to slice $12 billion from Amgen’s market value? And why are STAT’s D.C. correspondents working so hard?

We talk about all that and more on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. It’s a “Chatty Cathy” episode! Elaine, Allison and Adam lead off with a discussion about AbbVie’s M&A miscue following the failure of a closely followed schizophrenia drug. You’d hate us if obesity drugs weren’t mentioned, so we oblige with a tick-tock on what went down between Amgen and a Wall Street analyst who noted a possible safety issue with the obesity drug candidate MariTide.

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks Nov 07, 2024

Show notes

To dig into how the election results could affect all things biopharma, we brought on three guests for this episode: Lizzy Lawrence, STAT’s FDA reporter, Baird analyst Brian Skorney, and longtime biotech executive Daphne Zohar.

329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story Oct 31, 2024

Show notes

Adam, Allison, and Elaine get into the Halloween spirit this week, discussing their favorite candies — and Eli Lilly and Pfizer's surprise earnings reports. Then, they discuss what a Trump or Harris presidency could mean for health care and the biopharma industry, and what investors and biopharma executives think about either outcome.

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions Oct 24, 2024

Show notes

Will an activist investor campaign against Pfizer lead to big changes at the struggling Pharma giant? Why are some experts questioning the regulatory standards used to approve gene therapies for Duchenne muscular dystrophy? What’s the difference between Novo Holdings and Novo Nordisk, and will it impact a $16 billion acquisition of Catalent? And what lies ahead for Robert F. Kennedy Jr. and the Make America Healthy Again movement?

327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights Oct 17, 2024

Show notes

Elaine, Allison, and Adam chat about investors' interest in using CAR-T to treat autoimmune conditions, the latest developments with the supply of Eli Lilly’s blockbuster weight loss drug, and the invisible medical groups behind the dozens of telehealth platforms providing GLP-1 drugs. They also look back at STAT's two-day summit that brought together biopharma executives, scientists, policymakers and patient advocates for conversations about the future of health care.

326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI Oct 10, 2024

Show notes

First, biotech veteran John Maraganore calls in to discuss his new startup, City Therapeutics, this week's Nobel Prize awards, and the nerdy accolade he just received. Then STAT's Megan Molteni tells us about "CRISPR baby" scientist He Jiankui and his new cryptocurrency financier.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected